文献速递食管与纵隔外科

围手术期化疗与新辅助放化疗在局部晚期可切除食管腺癌中的全国性分析

Neoadjuvant chemoradiation versus perioperative chemotherapy in locally advanced resectable esophageal adenocarcinoma: A national analysis.
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-05-08

基于美国国家癌症数据库2016—2023年7387例接受食管切除术的局部晚期食管腺癌患者,比较围手术期化疗与新辅助放化疗的生存结局。围手术期化疗组462例(6%),新辅助放化疗组6925例(94%);5年总生存率分别为49%和42%。风险调整后围手术期化疗在1、3、5年的生存均优于新辅助放化疗,支持ESOPEC试验的早期发现。

要点

  • 围手术期化疗组5年总生存率49%,新辅助放化疗组42%。
  • 风险调整后围手术期化疗1年HR 0.66、3年HR 0.76、5年HR 0.80,均优于新辅助放化疗。
  • 围手术期化疗组限制性平均生存时间获益为3.7个月(95%CI 0.01-7.5个月)。

核心结论

  • 在接受食管切除术的局部晚期食管腺癌患者中,围手术期化疗较新辅助放化疗与更优的5年生存相关。
  • 该结果支持ESOPEC试验的早期发现,提示围手术期化疗可作为此类患者多模式治疗的首选考虑。

研究设计与样本

  • 回顾性分析2016—2023年美国国家癌症数据库(National Cancer Database)中临床分期T1N+M0或T2-4aN±M0、年龄≥18岁的食管腺癌患者。
  • 仅纳入接受食管切除术者,共7387例;围手术期多药化疗组462例(6%),新辅助化疗联合≥41.4 Gy放疗组6925例(94%)。

主要发现

  • 围手术期化疗组平均年龄更轻,性别、CDI和平均肿瘤大小与新辅助放化疗组相似。
  • 5年总生存率围手术期化疗组为49%,新辅助放化疗组为42%。
  • 风险调整后,相对新辅助放化疗,围手术期化疗1年HR 0.66(95%CI 0.48-0.90)、3年HR 0.76(95%CI 0.62-0.93)、5年HR 0.80(95%CI 0.66-0.97)。
  • 限制性平均生存时间分析显示围手术期化疗的生存获益为3.7个月(95%CI 0.01-7.5个月)。

关键数值与推荐

  • 新辅助放化疗定义:新辅助化疗联合≥41.4 Gy放疗。
  • 围手术期化疗定义:围手术期多药化疗。
  • 入组临床分期:T1N+M0或T2-4aN±M0。

临床怎么用

  • 对可切除局部晚期食管腺癌,围手术期化疗可作为多模式治疗的首选方案加以考虑。
  • 治疗决策需结合患者年龄与耐受性,并参考ESOPEC试验等证据综合评估。

局限性

  • 为回顾性数据库分析,存在选择偏倚与未测量混杂。
  • 围手术期化疗组样本量明显小于新辅助放化疗组(462例对6925例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is ongoing debate regarding the optimal multimodal treatment for patients with resectable locally advanced esophageal adenocarcinoma, with the recent ESOPEC trial suggesting perioperative chemotherapy to yield superior survival compared with Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) neoadjuvant chemoradiation. Providing a contemporary perspective, we sought to elucidate survival outcomes among a national cohort. METHODS: We performed a retrospective analysis of all clinically staged T1N+M0 or T2-4aN±M0 esophageal adenocarcinoma patients ≥18 years within the 2016-2023 National Cancer Database. Only patients who underwent esophagectomy were considered. Those who received neoadjuvant chemotherapy and ≥41.4 Gy radiation were grouped as Neoadjuvant-CR, whereas patients treated with perioperative multi-agent chemotherapy were considered Perioperative-Chemo. RESULTS: Of 7387 patients who underwent esophagectomy, 462 (6%) received Perioperative-Chemo and 6925 (94%) Neoadjuvant-CR. On average, and relative to Neoadjuvant-CR, the Perioperative-Chemo was incrementally younger, but of similar sex, CDI, and mean tumor size. Overall survival at 5 years was 49% for Perioperative-Chemo and 42% for Neoadjuvant-CR. After risk adjustment, and relative to receipt of neoadjuvant chemoradiation, treatment with perioperative chemotherapy was linked with improved survival at 1 (hazard ratio [HR], 0.66; 95% CI, 0.48-0.90), 3 (HR, 0.76; CI, 0.62-0.93), and 5 years (HR, 0.80; CI, 0.66-0.97). Restricted mean survival time analysis was used to quantify the survival benefit of perioperative chemotherapy at 3.7 months (CI, 0.01-7.5 months). CONCLUSIONS: Among patients who underwent esophagectomy, treatment with perioperative chemotherapy was linked with superior survival over 5 years, relative to neoadjuvant chemoradiotherapy. Our work supports the early findings of the ESOPEC trial and suggests perioperative chemotherapy should be considered upfront in the multimodal treatment of these complex patients.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Sakowitz S, Bakhtiyar SS, Sanaiha Y, et al. Neoadjuvant chemoradiation versus perioperative chemotherapy in locally advanced resectable esophageal adenocarcinoma: A national analysis. J Thorac Cardiovasc Surg. 2026. PMID: 42107635. doi:10.1016/j.jtcvs.2026.04.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。